Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia

Schizophrenia Research

Volumn 169, Issue 1-3, 2015, Pages 83-88

  Dean, Brian ^a,b   Thomas, Natalie ^a,b   Lai, Chi Yu ^a,c   Chen, Wei J ^c   Scarr, Elizabeth ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; PIRENZEPINE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; 4-DIPHENYLACETOXY-1,1-DIMETHYLPIPERIDINIUM; DLG4 PROTEIN, HUMAN; MEMBRANE PROTEIN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SIGNAL PEPTIDE; SNAP25 PROTEIN, HUMAN; TRITIUM;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN LEVEL; CHOLINERGIC SYSTEM; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLUTAMATERGIC SYSTEM; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; MOTIVATION; MOTOR CONTROL; NERVOUS SYSTEM; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; SCHIZOPHRENIA; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; AUTORADIOGRAPHY; GLIA; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; RADIOASSAY;

AUTORADIOGRAPHY; BLOTTING, WESTERN; CORPUS STRIATUM; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEUROGLIA; NEURONS; PIPERIDINES; PIRENZEPINE; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TRITIUM;

EID: 84953837185     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.10.028     Document Type: Article

References (48)

1. Alcantara A.A., Mrzljak L., Jakab R.L., Levey A.I., Hersch S.M., Goldman-Rakic P.S. Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways. J. Comp. Neurol. 2001, 434(4):445-460.
2. Beckmann H., Lauer M. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Res. 1997, 68(2-3):99-109.
3. Bernard V., Laribi O., Levey A.I., Bloch B. Subcellular redistribution of m2 muscarinic acetylcholine receptors in striatal interneurons in vivo after acute cholinergic stimulation. J. Neurosci. 1998, 18(23):10207-10218.
4. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000, 23(3):120-126.
5. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 2001, 41:237-260.
6. Conn P.J., Jones C.K., Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. TIPS 2009, 30(3):148-155.
7. Cook R.D., Weisberg S. Applied Regression Including Computing and Graphics 1999, Wiley, Hoboken.
8. Crook J.M., Dean B., Pavey G., Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci. 1999, 64(19):1761-1771.
9. D'Agostino R.B., Belanger A., D'Agostino R.B. A suggestion for using powerful and informative tests of normality. Am. Stat. 1990, 44:316-321.
10. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol. Psychiatry 1996, 1(1):54-58.
11. Dean B., Crook J.M., Pavey G., Opeskin K., Copolov D.L. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. Mol. Psychiatry 2000, 5(2):203-207.
12. Dean B., Gray L., Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust. N. Z. J. Psychiatry 2006, 40(3):217-224.
13. Dean B., McLeod M., Keriakous D., McKenzie J., Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2002, 7(10):1083-1091.
14. Dean B., Pavey G., Chai S.Y., Mendelsohn F.A.O. The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. Using CNS Tissue in Psychiatric Research: A Practical Guide 1999, 67-83. Harwood Academic Press, Amsterdam. B. Dean, J.E. Kleinman, T.M. Hyde (Eds.).
15. Falke E., Han L.Y., Arnold S.E. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 2000, 93(2):103-110.
16. Ferrer I., Santpere G., Arzberger T., Bell J., Blanco R., Boluda S., Budka H., Carmona M., Giaccone G., Krebs B., Limido L., Parchi P., Puig B., Strammiello R., Strobel T., Kretzschmar H. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe study. J. Neuropathol. Exp. Neurol. 2007, 66(1):35-46.
17. Gibbons A.S., Scarr E., Boer S., Money T., Jeon W.J., Felder C., Dean B. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int. J. Neuropsychopharmacol. 2012, 1-10.
18. Gylys K.H., Fein J.A., Yang F., Cole G.M. Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex. Cytometry A 2004, 60(1):90-96.
19. Haber S.N., Adler A., Bergman H. The basal ganglia. The Human Nervous System 2011, 678-719. Elsevier Science, Burlington. 3rd ed. J.K. Mai, G. Paxinos (Eds.).
20. Han M., Newell K., Zavitsanou K., Deng C., Huang X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J. Neurosci. Res. 2008, 86(2):457-464.
21. Hill C., Keks N., Roberts S., Opeskin K., Dean B., Mackinnon A., Copolov D. Problem of diagnosis in postmortem brain studies of schizophrenia. Am. J. Psychiatr. 1996, 153(4):533-537.
22. Jeon W.J., Gibbons A.S., Dean B. The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 47:7-12.
23. Joyce J.N., Lexow N., Bird E., Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988, 2(5):546-557.
24. Kingsbury A.E., Foster O.J., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res. Mol. Brain Res. 1995, 28(2):311-318.
25. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58(2):165-171.
26. Kristiansen L.V., Meador-Woodruff J.H. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr. Res. 2005, 78(1):87-93.
27. Mancama D., Arranz M.J., Landau S., Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 119(1):2-6.
28. McCullumsmith R.E., Kristiansen L.V., Beneyto M., Scarr E., Dean B., Meador-Woodruff J.H. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 2007, 1127(1):108-118.
29. Miller G.A., Chapman J.P. Misunderstanding analysis of covariance. J. Abnorm. Psychol. 2001, 110(1):40-48.
30. Miller J.H., Gibson V.A., McKinney M. Binding of [3H]AF-DX 384 to cloned and native muscarinic receptors. J. Pharmacol. Exp. Ther. 1991, 259(2):601-607.
31. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363(9426):2063-2072.
32. Pavey G.M., Copolov D.L., Dean B. High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding. J. Neurosci. Methods 2002, 116(2):157-163.
33. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999, 22(6):273-280.
34. Raedler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 2007, 12(3):232-246.
35. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., Egan M.F., Coppola R., Weinberger D.R. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatr. 2003, 160(1):118-127.
36. Roberts S.B., Hill C.A., Dean B., Keks N.A., Opeskin K., Copolov D.L. Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust. N. Z. J. Psychiatry 1998, 32(1):73-76.
37. Salah-Uddin H., Scarr E., Pavey G., Harris K., Hagan J.J., Dean B., Challiss R.A., Watson J.M. Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology 2009, 34(9):2156-2166.
38. Scarr E., Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. J. Neurochem. 2008, 107(5):1188-1195.
39. Scarr E., Cowie T.F., Kanellakis S., Sundram S., Pantelis C., Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry 2009, 14(11):1017-1023.
40. Scarr E., Craig J.M., Cairns M.J., Seo M.S., Galati J.C., Beveridge N.J., Gibbons A., Juzva S., Weinrich B., Parkinson-Bates M., Carroll A.P., Saffery R., Dean B. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Transcult. Psychiatry 2013, 3:e230.
41. Scarr E., Gibbons A.S., Neo J., Udawela M., Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front. Cell. Neurosci. 2013, 7:55.
42. Scarr E., Gray L., Keriakous D., Robinson P.J., Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord. 2006, 8(2):133-143.
43. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatr. 2008, 165(8):1033-1039.
44. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119(1):7-35.
45. Stan A.D., Ghose S., Gao X.M., Roberts R.C., Lewis-Amezcua K., Hatanpaa K.J., Tamminga C.A. Human postmortem tissue: what quality markers matter?. Brain Res. 2006, 1123(1):1-11.
46. Terry A.V., Gearhart D.A., Mahadik S.P., Warsi S., Waller J.L. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 2006, 140(4):1277-1287.
47. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
48. Zhang W., Yamada M., Gomeza J., Basile A.S., Wess J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J. Neurosci. 2002, 22(15):6347-6352.